108 related articles for article (PubMed ID: 35731106)
61. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases.
Srodon M; Westra WH
Hum Pathol; 2002 Jun; 33(6):642-5. PubMed ID: 12152164
[TBL] [Abstract][Full Text] [Related]
62. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
[TBL] [Abstract][Full Text] [Related]
63. K-ras and rho A mutations in malignant pleural effusion.
Nakamoto M; Teramoto H; Matsumoto S; Igishi T; Shimizu E
Int J Oncol; 2001 Nov; 19(5):971-6. PubMed ID: 11604996
[TBL] [Abstract][Full Text] [Related]
64. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions.
Jang KY; Kang MJ; Lee DG; Chung MJ
Anal Quant Cytol Histol; 2001 Dec; 23(6):400-4. PubMed ID: 11777274
[TBL] [Abstract][Full Text] [Related]
65. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
66. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
67. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
68. Clinical significance of the detection of the homozygous deletion of P16 gene in malignant pleural effusion.
Gui S; Liu H; Zhang L; Zuo L; Zhou Q; Fei G; Wang Y
Intern Med; 2007; 46(15):1161-6. PubMed ID: 17675763
[TBL] [Abstract][Full Text] [Related]
69. Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids.
Gomez-Fernandez C; Jorda M; Delgado PI; Ganjei-Azar P
Cancer; 2002 Oct; 96(5):289-93. PubMed ID: 12378596
[TBL] [Abstract][Full Text] [Related]
70. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.
Liu L; Shao D; Deng Q; Tang H; Wang J; Liu J; Guo F; Lin Y; Peng Z; Mao M; Kristiansen K; Ye M; He J
J Thorac Dis; 2018 May; 10(5):2631-2637. PubMed ID: 29997924
[TBL] [Abstract][Full Text] [Related]
71. Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples.
Roy Chowdhuri S; Hanson J; Cheng J; Rodriguez-Canales J; Fetsch P; Balis U; Filie AC; Giaccone G; Emmert-Buck MR; Hipp JD
Acta Cytol; 2012; 56(6):622-31. PubMed ID: 23207440
[TBL] [Abstract][Full Text] [Related]
72. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
73. Multiplexed molecular profiling of lung cancer using pleural effusion.
Akamatsu H; Koh Y; Kenmotsu H; Naito T; Serizawa M; Kimura M; Mori K; Imai H; Ono A; Shukuya T; Taira T; Murakami H; Ohde Y; Endo M; Nakajima T; Takahashi T; Yamamoto N
J Thorac Oncol; 2014 Jul; 9(7):1048-1052. PubMed ID: 24926551
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of serum and pleural levels of soluble B7-H4 in lung cancer patients with pleural effusion.
Xu C; Qian L; Yu L; Zhang X; Wang Q
Biomarkers; 2015; 20(4):271-4. PubMed ID: 26301886
[TBL] [Abstract][Full Text] [Related]
75. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
76. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.
Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP
Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505
[TBL] [Abstract][Full Text] [Related]
77. Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Cappellesso R; Nicolè L; Caroccia B; Guzzardo V; Ventura L; Fassan M; Fassina A
Cancer Cytopathol; 2016 Jan; 124(1):28-37. PubMed ID: 26765063
[TBL] [Abstract][Full Text] [Related]
78. High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.
Zhao C; Li X; Su C; Li J; Cheng N; Ren S; Chen X; Zhou C
Int J Clin Exp Pathol; 2015; 8(3):3104-9. PubMed ID: 26045824
[TBL] [Abstract][Full Text] [Related]
79. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS
Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132
[TBL] [Abstract][Full Text] [Related]
80. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
Wu M; Szporn AH; Zhang D; Wasserman P; Gan L; Miller L; Burstein DE
Diagn Cytopathol; 2005 Oct; 33(4):223-7. PubMed ID: 16138374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
